India plans to substantially increase its production-linked incentives for the pharmaceutical industry. The new PLI scheme will cover additional molecules that are used to produce critical starting materials, pharma intermediates, and APIs. As an API manufacturer, what will this step do for your business in the long term?
The new PLI scheme is a well-timed and very welcome development. As India's first vertically integrated virtual API company, HRV has much to gain. We run an asset-light business that focuses on bringing a unique portfolio of products while consolidating underutilised capacities of USFDA/EUGMP-compliant Indian manufacturers.
By broadening the pool of eligible molecules under PLI, we are able to commercialise niche, complex, and high-barrier APIs with more agility. This will support our goal of adding 25+ new products every year and assist India in minimising dependency on imports, especially of key starting materials (KSMs) and intermediates. For us, it increases our capabilities of serving faster, more economical, and compliant APIs into many international markets, while creating resilience in India's very own pharma backbone.
In spite of some government incentives, what are the other issues besetting India's pharma industry?
Although policy support has enhanced, the pharma industry continues to face challenges:
We at HRV have established a centralised regulatory group, an AI platform proprietary to us, and moving to dual sourcing arrangements to mitigate these issues.
Do you continue to view China as a leading API producer or has India managed to put its stamp on API production?
China remains dominant in basic intermediates and KSMs, but India is leading the way in APIs alongside China. It’s an inseparable relationship. Our speed to market and regulatory-first mindset have made Indian API suppliers the go-to partners in a post-COVID world where trust and resilience matter more than ever.
It’s no longer a low-cost production in India— today, we're establishing confidence, accuracy, and regulatory stability at scale.
What are you doing in terms of sustainable packaging?
Sustainability is not an afterthought—it’s built into our supply chain orchestration model.
We have implemented & are working on some of these new areas in future -
We are also exploring green logistics fleets through partnerships for intra-India movement. Our goal is to transition 50 per cent of our bulk shipments to eco-friendly packaging formats by FY 2027, if not earlier.
What will be your latest innovations in the API space?
HRV is focused on innovation across three dimensions:
This mix lets us win on speed, scarcity, and compliance—not price alone.
Who are your key exporters for API? How big is the API business?
We now export to more than 15 countries. Key geographies in the order of volumes are:
Our API business grossed more than Rs 400 crore in FY 2024–25. Both regulated and semi-regulated market supplies from therapeutic categories such as oncology, gynaecology, rare diseases and general medicine are included.
We address Tier-1 customers and governments through our compliance-driven model—submitting DMFs, driving audits, and having quality assurance end-to-end ownership.
What are your plans for expansion to other international markets?
We are following a systematic three-tier expansion strategy:
Your India plans in the coming years?
India is our research lab, our regulatory sandbox, and our greatest pool of scientific strength.
Our short-term India priorities are:
In short, we’re not just aggregating capacity—we’re curating innovation, scaling trust, and turning India, my homeland, into the global headquarters for compliant API sciences.
India’s manufacturing talent and scientific rigour are unmatched—and we’re helping package it for the world.
How much revenue did you generate in the previous financial year and what are your projections for the next FY?
We closed FY 2024–25 with consolidated revenues of Rs 419 crore, growing at a CAGR of more than 70 per cent over the past seven years. We are debt free company with a Return on Capital Employed (ROCE) of over 40 per cent.
For FY 2025–26, we're looking to achieve organic revenues of Rs 550–600 crore, with strong possibilities of growing to a $100 million company (over Rs 850 crore). We will have continued emphasis on:
We’re not just scaling products—we’re scaling trust.
Sanjiv Das
sanjiv.das@mmactiv.com